Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group (Q39876026)
Jump to navigation
Jump to search
scientific article published on September 1996
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group |
scientific article published on September 1996 |
Statements
1 reference
Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group (English)
1 reference
Schooley RT
1 reference
Larder BA
1 reference
Kohli A
1 reference
Bloor S
1 reference
Kemp SD
1 reference
Harrigan PR
1 reference
Lange JM
1 reference
Pennington KN
1 reference
St Clair MH
1 reference
1 September 1996
1 reference
1 reference
1 reference
1 reference
1 reference